Table 3.

Performance metrics for predicting whether patients survive longer than the group median in EGFR, ALK, and KRAS mutation-positive groups.

Mutation	Accuracy	AUC*	Sensitivity	Specificity
EGFR	94.90%	0.977	96.00%	94.00%
ALK	84.10%	0.905	88.00%	81.00%
KRAS	83.00%	0.947	83.00%	83.00%

^*AUC, area under the receiver operating characteristic curve.

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog.

Both clinical data and radiomics features were used for predictive modeling.